Product logins

Find logins to all Clarivate products below.


Biosimilars | Market Events and Forecast | Neurology | 2025

In 2023, sales of branded MAb biologics in neurology exceeded $10 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2023-2033 forecast period, the reference brands Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are set to lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these key reference brands and their biosimilars by molecule and country / region.

Related Market Assessment Reports

Report
Muscular Dystrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…
Report
Biosimilars – Access & Reimbursement – Payer Insights Landscape (US/EU)
Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…
Report
Alzheimer’s Disease – Geographic Focus: China – China In-Depth – Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder characterized by cognitive decline, memory impairment, and loss of functional independence. In China, current…
Report
Biosimilars – Corporate Strategies – Biosimilar Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…
Report
Biosimilars – Corporate Strategies – Reference Brand Developer Strategies
The commercial opportunity available to biosimilars manufacturers is undeniably large, but developing a strategy that will capture a profitable share of the market is challenging. Unlike the…